Methoxamine clinical trials
Also written NRL001.
Includes 1 study of Methoxamine, (+)-.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses Methoxamine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 28 Mar 1949 · VASOXYL · NDA 006772 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NRL001
- 6
Studies by the year they started
8 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses Methoxamine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment PeriodCompletedPhase 2NorgineNCT01656720Written as 1R, 2S-methoxamine hydrochloride
- Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal IncontinenceCompletedPhase 1NorgineNCT01175941Written as NRL001
- Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy VolunteersCompletedPhase 1NorgineNCT01406925Written as NRL001 cream
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 DaysCompletedPhase 1NorgineNCT01099670Written as NRL001
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly SubjectsCompletedPhase 1NorgineNCT01099683Written as NRL001
- Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.CompletedPhase 1NorgineNCT00857467Written as NRL001
- Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different WeightsCompletedPhase 1NorgineNCT00850590Written as NRL001
- Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or RectumCompletedPhase 1NorgineNCT00893607Written as NRL001
Codes
What other systems call Methoxamine · ClinicalTrials.gg INT007809
- MeSH (NLM) D008729MethoxamineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) HUQ1KC1YLIMETHOXAMINEConfirmed FDA, NLM
- RxNorm 6853One source FDA
- NCI Thesaurus C66119MethoxamineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D008729 | Methoxamine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | HUQ1KC1YLI | METHOXAMINE | Confirmed FDA, NLM |
| RxNorm | 6853 | — | One source FDA |
| NCI Thesaurus | C66119 | Methoxamine | One source FDA |
Also registered as methoxamine hydrochloride (UNII 8MB4MJ9R7L · RxNorm 203187).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.